BTAI BioXcel Therapeutics Inc

Price (delayed)

$12.12

Market cap

$339.18M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.11

Enterprise value

$139.77M

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically ...

Highlights
BTAI's debt is down by 23% year-on-year and by 7% since the previous quarter
The equity has declined by 12% since the previous quarter but it is up by 3.9% year-on-year
BioXcel Therapeutics's net income has decreased by 20% YoY and by 4.8% QoQ
BTAI's quick ratio is down by 20% year-on-year and by 10% since the previous quarter

Key stats

What are the main financial stats of BTAI
Market
Shares outstanding
27.99M
Market cap
$339.18M
Enterprise value
$139.77M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.75
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$111.99M
EBITDA
-$111.68M
Free cash flow
-$95.18M
Per share
EPS
-$4.11
Free cash flow per share
-$3.4
Book value per share
$6.93
Revenue per share
$0
TBVPS
$7.54
Balance sheet
Total assets
$211.05M
Total liabilities
$17.03M
Debt
$1.03M
Equity
$194.02M
Working capital
$191.57M
Liquidity
Debt to equity
0.01
Current ratio
12.98
Quick ratio
12.53
Net debt/EBITDA
1.79
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-45.1%
Return on equity
-48.3%
Return on invested capital
N/A
Return on capital employed
-57.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BTAI stock price

How has the BioXcel Therapeutics stock price performed over time
Intraday
0.5%
1 week
17.33%
1 month
5.85%
1 year
-61.04%
YTD
-40.38%
QTD
-42.04%

Financial performance

How have BioXcel Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$112.04M
Net income
-$112.03M
Gross margin
N/A
Net margin
N/A
BioXcel Therapeutics's net income has decreased by 20% YoY and by 4.8% QoQ
The company's operating income fell by 20% YoY and by 4.8% QoQ

Growth

What is BioXcel Therapeutics's growth rate over time

Valuation

What is BioXcel Therapeutics stock price valuation
P/E
N/A
P/B
1.75
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
BTAI's price to book (P/B) is 67% lower than its 5-year quarterly average of 5.2 and 40% lower than its last 4 quarters average of 2.9
The equity has declined by 12% since the previous quarter but it is up by 3.9% year-on-year

Efficiency

How efficient is BioXcel Therapeutics business performance
The company's return on equity rose by 14% YoY but it fell by 4.1% QoQ
BioXcel Therapeutics's return on assets has increased by 12% YoY but it has decreased by 3.7% QoQ

Dividends

What is BTAI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BTAI.

Financial health

How did BioXcel Therapeutics financials performed over time
BTAI's total liabilities is up by 25% YoY but it is down by 4.2% QoQ
BTAI's quick ratio is down by 20% year-on-year and by 10% since the previous quarter
BTAI's debt is 99% smaller than its equity
BTAI's debt is down by 23% year-on-year and by 7% since the previous quarter
The equity has declined by 12% since the previous quarter but it is up by 3.9% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.